Testing effectiveness (Phase 2)Study completedNCT00901342What this trial is testingOpen Label Study of Sipuleucel-T in Metastatic Prostate CancerWho this might be right forProstate Cancer Dendreon 104
Not applicableUnknownNCT04833517What this trial is testingProspective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)Who this might be right forProstate Cancer MetastaticCastration Resistant Prostatic CancerAdvanced Prostate Carcinoma Universität des Saarlandes 500
Testing effectiveness (Phase 2)Study completedNCT01540071What this trial is testingTrial of NRX 194204 in Castration- and Taxane-Resistant Prostate CancerWho this might be right forCastration Resistant Prostate Cancer Io Therapeutics 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511What this trial is testingAn Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCWho this might be right forMetastatic Castration Resistant Prostate Cancer (mCRPC) Novartis Pharmaceuticals 7
Not applicableStudy completedNCT02669147What this trial is testingDetermine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPCWho this might be right forCastration Resistant Prostate Cancer (CRPC) Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 160
Early research (Phase 1)Study completedNCT04786847What this trial is testing177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry StudyWho this might be right forMetastatic Prostate Cancer Telix Pharmaceuticals (Innovations) Pty Limited 30
Not applicableStudy completedNCT00455624What this trial is testingProspective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate CancerWho this might be right forProstate Cancer Massachusetts General Hospital 60
Testing effectiveness (Phase 2)Ended earlyNCT01996696What this trial is testingPrevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the ProstateWho this might be right forProstatic Neoplasm AHS Cancer Control Alberta 83
Testing effectiveness (Phase 2)Looking for participantsNCT06039371What this trial is testingSupraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA StudyWho this might be right forCastration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8 University of Washington 69
Early research (Phase 1)Study completedNCT03575819What this trial is testingFOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Who this might be right forProstate Cancer Metastatic Fortis Therapeutics, Inc. 56
Testing effectiveness (Phase 2)Study completedNCT00666666What this trial is testingR-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate CancerWho this might be right forAdenocarcinoma of the ProstateStage IV Prostate Cancer National Cancer Institute (NCI) 55
Post-approval studies (Phase 4)Active Not RecruitingNCT03016741What this trial is testingCognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate CancerWho this might be right forCastration-Resistant Prostatic CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+2 more Northwestern University 100
Testing effectiveness (Phase 2)Ended earlyNCT02379390What this trial is testingCabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or EnzalutamideWho this might be right forProstate Cancer Metastatic Sanofi 8
Post-approval studies (Phase 4)Study completedNCT02918968What this trial is testingStudy on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate CancerWho this might be right forProstate Cancer Astellas Pharma Inc 206
Testing effectiveness (Phase 2)Ended earlyNCT04754425What this trial is testingErdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerWho this might be right forCastration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Malignant Neoplasm in the Bone+5 more M.D. Anderson Cancer Center 11
Post-approval studies (Phase 4)Looking for participantsNCT05348876What this trial is testingLearn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)Who this might be right forNon-metastatic Castration-resistant Prostate Cancer Bayer 50
Testing effectiveness (Phase 2)Study completedNCT02217566What this trial is testingStudy of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol TherapyWho this might be right forProstatic Neoplasms Janssen Research & Development, LLC 46
Testing effectiveness (Phase 2)Ended earlyNCT05551117What this trial is testingVobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsWho this might be right forCastration-Resistant Prostatic CancerAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic Cancer+14 more MacroGenics 192
Testing effectiveness (Phase 2)Study completedNCT02097303What this trial is testingOpen Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone MetastasisWho this might be right forProstate Cancer Carolina Research Professionals, LLC 36
Early research (Phase 1)Ended earlyNCT04279561What this trial is testingEffect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate CancerWho this might be right forCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8+2 more Jonsson Comprehensive Cancer Center 9